
Quarterly report 2025-Q3
added 11-19-2025
Dynatronics Corporation EBITDA 2011-2026 | DYNT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Dynatronics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.97 M | -1.59 M | -4.13 M | -4.02 M | -2.91 M | -1.26 M | 815 K | 61 K | -1.34 M | -1.38 M | -691 K | 395 K | 658 K | 475 K | 1.12 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 M | -4.13 M | -1.05 M |
Quarterly EBITDA Dynatronics Corporation
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.7 K | - | - | -95.8 K | - | - | -73.7 K | - | - | -800 K | -291 K | -906 K | -1.44 M | -1.4 M | -250 K | -1.47 M | -600 K | -597 K | -99.3 K | -159 K | -99.3 K | -32.2 K | 476 K | 463 K | 476 K | -92.8 K | 250 K | 188 K | 181 K | 107 K | 333 K | 291 K | 197 K | -87.4 K | -302 K | -194 K | -302 K | -46 K | -165 K | -157 K | -165 K | -151 K | 9.28 K | -326 K | 9.28 K | 123 K | -220 K | -90.9 K | -220 K | 259 K | -124 K | 476 K | 94.6 K | 114 K | 50 K | 314 K | 50 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 476 K | -1.47 M | -127 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 11.1 | -0.72 % | $ 314 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Electromed
ELMD
|
10.7 M | $ 25.81 | 0.98 % | $ 218 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.16 | - | $ 1.31 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.45 | 3.29 % | $ 129 M | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.61 | -2.42 % | $ 38 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 11.53 | 4.63 % | $ 413 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 57.59 | -2.51 % | $ 3.14 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.48 | -1.44 % | $ 65.5 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Insulet Corporation
PODD
|
564 M | $ 167.53 | -2.25 % | $ 11.8 B | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 48.25 | -12.02 % | $ 1.42 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.05 | -3.23 % | $ 17.8 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.42 | - | $ 6.71 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 17.04 | 7.98 % | $ 400 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.82 | -0.52 % | $ 1.02 B | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
TransMedics Group
TMDX
|
136 M | $ 94.93 | -2.21 % | $ 3.23 B | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 19.42 | -2.26 % | $ 1.32 B | ||
|
Globus Medical
GMED
|
757 M | $ 90.03 | -0.63 % | $ 12.2 B | ||
|
NanoVibronix
NAOV
|
-22 M | - | - | $ 1.08 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.64 | 2.12 % | $ 1.14 B | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 295.25 | 1.5 % | $ 113 B | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.85 | 2.26 % | $ 2.98 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 82.91 | -0.5 % | $ 48.5 B | ||
|
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.27 | -4.51 % | $ 51.7 M | ||
|
MiMedx Group
MDXG
|
78.8 M | $ 3.64 | 0.83 % | $ 538 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.88 | 1.69 % | $ 36.8 M |